N 6-benzoyladenosine-3′,5′-cyclic monophosphate acetoxymethyl ester
8-(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate acetoxymethyl ester
Ca2+/calmodulin-regulated protein kinase II
cAMP-regulated guanine nucleotide exchange factor
Ca2+-induced Ca2+ release
exchange protein directly activated by cAMP
Epac-selective cAMP analogue acetoxymethyl ester
enhanced yellow fluorescent protein
glucagon-like peptide-1 receptor
G protein-coupled receptor
nicotinic acid adenine dinucleotide phosphate
o-nitrophenyl ethylene glycol tetraacetic acid
- Phosphate AM3
phosphate tris (acetoxymethyl) ester
protein kinase A
protein kinase C
standard extracellular saline
voltage-dependent Ca2+ channels
Calcium can be mobilized in pancreatic β-cells via a mechanism of Ca2+-induced Ca2+ release (CICR), and cAMP-elevating agents such as exendin-4 facilitate CICR in β-cells by activating both protein kinase A and Epac2. Here we provide the first report that a novel phosphoinositide-specific phospholipase C-ɛ (PLC-ɛ) is expressed in the islets of Langerhans, and that the knockout (KO) of PLC-ɛ gene expression in mice disrupts the action of exendin-4 to facilitate CICR in the β-cells of these mice. Thus, in the present study, in which wild-type (WT) C57BL/6 mouse β-cells were loaded with the photolabile Ca2+ chelator NP-EGTA, the UV flash photolysis-catalysed uncaging of Ca2+ generated CICR in only 9% of the β-cells tested, whereas CICR was generated in 82% of the β-cells pretreated with exendin-4. This action of exendin-4 to facilitate CICR was reproduced by cAMP analogues that activate protein kinase A (6-Bnz-cAMP-AM) or Epac2 (8-pCPT-2′-O-Me-cAMP-AM) selectively. However, in β-cells of PLC-ɛ KO mice, and also Epac2 KO mice, these test substances exhibited differential efficacies in the CICR assay such that exendin-4 was partly effective, 6-Bnz-cAMP-AM was fully effective, and 8-pCPT-2′-O-Me-cAMP-AM was without significant effect. Importantly, transduction of PLC-ɛ KO β-cells with recombinant PLC-ɛ rescued the action of 8-pCPT-2′-O-Me-cAMP-AM to facilitate CICR, whereas a K2150E PLC-ɛ with a mutated Ras association (RA) domain, or a H1640L PLC-ɛ that is catalytically dead, were both ineffective. Since 8-pCPT-2′-O-Me-cAMP-AM failed to facilitate CICR in WT β-cells transduced with a GTPase activating protein (RapGAP) that downregulates Rap activity, the available evidence indicates that a signal transduction ‘module’ comprised of Epac2, Rap and PLC-ɛ exists in β-cells, and that the activities of Epac2 and PLC-ɛ are key determinants of CICR in this cell type.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.
Calcium-induced Ca2+ release (CICR) can occur in pancreatic β-cells (Islam et al. 1992; Lemmens et al. 2001; Beauvois et al. 2004), and β-cell cAMP-elevating agents such as glucagon-like peptide-1 (GLP-1) or the GLP-1 receptor (GLP-1R) agonist exendin-4 mobilize an intracellular source of Ca2+ by facilitating CICR (Gromada et al. 1995; Holz et al. 1999; Dyachok & Gylfe, 2004). How cAMP elevating agents exert this effect is a topic of considerable interest in view of the fact that Ca2+ mobilized in this manner generates an increase of cytosolic Ca2+ concentration ([Ca2+]i) that is an adequate stimulus for β-cell exocytosis (Kang et al. 2003; Kang & Holz, 2003; Dyachok & Gylfe, 2004). One view is that the CICR mechanism of β-cells is dually governed by Ca2+ and cAMP such that the Ca2+ release mechanism operates at maximal efficiency when there is a coincident rise in Ca2+ and cAMP levels (Kang et al. 2001, 2003, 2005). This is a process of second messenger coincidence detection and it involves the activation of two principal types of cAMP binding proteins found in β-cells; protein kinase A (PKA) and the cAMP-regulated guanine nucleotide exchange factor designated as Epac2 (de Rooij et al. 1998; Kawasaki et al. 1998). Here we have investigated the molecular basis for cAMP-dependent control of CICR in β-cells, and we report that a novel phospholipase C-ɛ (PLC-ɛ; a product of the PLCE1 gene) couples cAMP production and Epac2 activation to the facilitation of CICR. Surprisingly, this Epac2- and PLC-ɛ-dependent mechanism of β-cell Ca2+ mobilization bears a striking resemblance to the CICR mechanism that is under the control of Epac1 and PLC-ɛ in cardiomyocytes (Oestreich et al. 2007, 2009).
Phospholipase C-ɛ is a phosphoinositide-specific PLC, the activity of which can be stimulated by ligand binding to G protein-coupled receptors (GPCRs) and also growth factor receptors (Kelley et al. 2001; Lopez et al. 2001; Song et al. 2001, 2002). For growth factor receptors, the activation of PLC-ɛ is mediated by Ras superfamily monomeric GTPases, whereas a subset of GPCRs can signal through heterotrimeric GTPases to activate PLC-ɛ (Kelley et al. 2004; Citro et al. 2007). Interestingly, studies of HEK-293 cells expressing β2-adrenergic GPCRs first demonstrated an ability of adrenaline to activate PLC-ɛ, and that this effect of adrenaline was both cAMP and Epac1 mediated (Schmidt et al. 2001). It was proposed that the cAMP-bound form of Epac1 signals through Rap GTPase to stimulate the activity of PLC-ɛ, and that this functional coupling is explained by the binding of Rap to a Rap association (RA) domain located within PLC-ɛ. Subsequently, this novel cAMP signalling mechanism was shown to mediate β1-adrenergic receptor regulation of CICR in adult mouse ventricular myocytes, thereby demonstrating a true physiological role for this pathway (Oestreich et al. 2007, 2009). Since Epac2 is expressed in β-cells (Ozaki et al. 2000), and since Rap1 transduces stimulatory effects of cAMP on insulin secretion (Shibasaki et al. 2007), an attractive hypothesis is that cAMP-elevating agents facilitate CICR, and possibly exocytosis, by virtue of their ability to stimulate PLC-ɛ activity, and that these actions of cAMP-elevating agents are mediated by Epac2 and Rap1.
We now provide the first evidence that PLC-ɛ is expressed in mouse and human islets of Langerhans. Using an assay for CICR that involves UV flash photolysis to uncage Ca2+ from o-nitrophenyl ethylene glycol tetraacetic acid (NP-EGTA), we also demonstrate that the Epac2-dependent action of GLP-1R agonist exendin-4 to facilitate CICR is lost in β-cells isolated from mice in which there is a knockout (KO) of Epac2, and also in mice in which there is a KO of PLC-ɛ. Furthermore, selective activation of Epac2 with 8-(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate acetoxymethyl ester (8-pCPT-2′-O-Me-cAMP-AM) facilitates CICR in wild-type (WT) mouse β-cells, but not in β-cells of Epac2 and PLC-ɛ KO mice. Since this action of 8-pCPT-2′-O-Me-cAMP-AM is entirely absent in β-cells of WT mice overexpressing a Rap GTPase activating protein (RapGAP) that downregulates the activity of Rap, it is concluded that a signal transduction ‘module’ comprised of Epac2, Rap and PLC-ɛ exists in β-cells, and that the activities of Epac2 as well as PLC-ɛ are key determinants of CICR in this cell type.
All experimental procedures reported here were in accordance with the ethical policy of The Journal of Physiology (Drummond, 2009) and were also in accordance with SUNY Upstate Medical University policies governing the ethical use of mice for experimentation (IACUC protocol no. 074). For studies involving the use of donor human islets, the islets were provided by the Islet Distribution Program (IIDP) funded by the NIH. These human islets were obtained from cadaver donors under conditions of informed consent, and appropriate safeguards were maintained for donor anonymity. Approval for the use of human islets was granted by the Institutional Review Board of SUNY Upstate Medical University.
Generation of PLC-ɛ knockout mice
Phospholipase C-ɛ KO mice with global disruption of PLCE1 gene expression (NCBI GeneID 74055) do not express either the long or the short form of PLC-ɛ. These PLC-ɛ KO mice were generated by the methods of homologous recombination in the laboratory of A. V. Smrcka at the University of Rochester School of Medicine (Wang et al. 2005). These PLC-ɛ KO mice have been used in prior studies of cardiomyocytes (Oestreich et al. 2007, 2009) and astrocytes (Citro et al. 2007). One phenotype of these mice is a cardiac contractility defect owing to a disruption of cardiomyocyte β-adrenergic receptor-dependent intracellular Ca2+ mobilization (Wang et al. 2005; Oestreich et al. 2007, 2009). For the studies described here, colonies of PLC-ɛ (−/−) KO mice and congenic heterozygous (+/−) or wild-type (WT; +/+) littermate mice located at SUNY Upstate Medical University were maintained on the C57BL/6 genetic background after six rounds of backcrossing with C57BL/6 mice obtained from Charles River Laboratories International Inc. (Wilmington, MA, USA).
Generation of Epac2 knockout mice
Epac2 KO mice with global disruption of RAPGEF4 gene expression (NCBI GeneID 56508) were generated in the laboratory of Y. Lu of Louisiana State University School of Medicine using a gene trapping approach (Tu et al. 2010). The embryonic stem cell clone used to create the Epac2 KO mouse was OST450264. For the studies described here, the Epac2 KO mice and wild-type littermate mice were maintained on the 129svEv genetic background without their having been backcrossed with any other strain of mice. Additional information concerning the characterization of the Epac2 KO mice is presented in the Supplemental Material.
Primary culture of mouse β-cells
The indicated strains of mice were fed a standard mouse chow (Formulab Diet, catalogue no. 5008). The mice were anaesthetized by isofluorane (4% in O2) administered by the inhalational route and killed by cervical dislocation. This method of killing is consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association, and it has received the approval of the SUNY Upstate Medical University Animal Care and Use Committee. The pancreas was removed and digested with Liberase TL Research Grade (Roche Applied Science, Indianapolis, IN, USA; catalogue no. 05-401-020-001). Batches of 150–200 islets were subjected to mild trypsinization and dispersed by trituration in a Ca2+-free saline in order to generate a single-cell suspension. Single cells were allowed to adhere to glass coverslips (25CIR-1; Fisher Scientific) coated with concanavalin A (type V; Sigma-Aldrich), and these primary cultures were maintained in a humidified incubator (95% air, 5% CO2) at 37°C in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 units ml−1 penicillin G and 100 mg ml−1 streptomycin. The β-cells were identified on the basis of their large diameter and granular appearance, or after immunodetection of insulin (see below).
Measurement of [Ca2+]i
The fura-2 loading solution consisted of a standard extracellular saline (SES) containing (mm): 138 NaCl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 10 Hepes and 5.6 d-glucose, supplemented with 1 μm fura-2 AM, 2% FBS and 0.02% Pluronic F-127 (w/v). Cells were immersed in the fura-2 loading solution for 20–30 min at 22°C, after which the solution was replaced with fresh SES. Experiments were performed at 32°C using a TE300 inverted microscope (Nikon, Melville, NY, USA) equipped with a temperature-controlled superfusion chamber (Medical Systems Corp., Greenvale, NY, USA) and a ×40 SuperFluor oil immersion objective (Nikon, NA 1.3). Microfluorimetry was performed ratiometrically at 1.0 s intervals using a dual excitation wavelength video imaging system outfitted with an intensified CCD camera (IonOptix Corp., Milton, MA, USA). A rotating mirror delivered the excitation light at 340 or 380 nm. The emitted light was measured at 510 nm, and the average of 29 frames of 340 or 380 nm excitation imaging data was used to calculate numerator and denominator values for determination of the 340/380 ratios after background subtraction. The value of [Ca2+]i was calculated according to established methods (Grynkiewicz et al. 1985), and the calibration was performed as described previously (Kang et al. 2001; Kang & Holz, 2003) using fura-2 [K+]5 salt dissolved in calibration buffers (Molecular Probes/Invitrogen Calcium Calibration Kit 1 with Mg2+). Values of Rmin and Rmax were 0.20 and 7.70.
Ultraviolet flash photolysis for the liberation of caged Ca2+
Methods for the uncaging of Ca2+ were as described in greater detail by Kang et al. (2005). Briefly, β-cells were bathed for 60 min at 23°C in SES containing cell-permeable caged Ca2+ (5 μm NP-EGTA-AM; Molecular Probes/Invitrogen). The loading solution also contained 1 μm fura-2 AM, 2% FBS and 0.02% Pluronic F-127. The uncaging of Ca2+ was achieved using a flash photolysis system (Model JML-C2; Rapp OptoElectronic, Hamburg, Germany). The excitation light of 80 J intensity and 600 μs duration was filtered using a short-pass filter (cut-off 390 nm) and was delivered through a liquid light guide to individual β-cells by way of the microscope objective. The intensity and duration of the flash were minimized so that no measurable photo-bleaching of fura-2 was observed. The intensity of 340 and 380 nm excitation light for detection of fura-2 was also reduced so as to be so low as to produce no measurable uncaging of Ca2+ (Kang et al. 2005).
Statistical analysis of CICR
Population studies were performed at the single-cell level in order to determine the percentage of cells exhibiting CICR in conditions in which the cells were treated with pharmacological agents added directly to the bath or applied to individual cells via ‘puffer’ pipettes. At least 10 cells per coverslip were selected, one at a time in random order, to determine basal [Ca2+]i and CICR amplitude. Calcium-induced Ca2+ release in mouse β-cells was defined as a transient increase of [Ca2+]i, the duration of which did not exceed 30 s when measured at the 10% amplitude cut-off (Fig. 1C). An additional requirement was that the increase of [Ca2+]i must have exceeded 200 nm when measured at the 50% amplitude cut-off (Fig. 1C). For these population studies, each experiment was performed in triplicate, and statistical analyses were performed using ANOVA combined with Fisher's PLSD test.
Adenoviral transduction of β-cells
Primary cultures of mouse β-cells were infected with adenovirus directing the expression of RapGAP, wild-type PLC-ɛ, a K2150E PLC-ɛ with a mutated RA2 domain that prevents Rap activation, and a H1640L PLC-ɛ that is catalytically dead. The properties of these adenoviral constructs in which there is bicistronic expression of Enhanced Yellow Flourescent Protein (EYFP) and RapGAP or PLC-ɛ have been described previously (Oestreich et al. 2009). Single β-cells maintained on glass coverslips were incubated in serum-free culture medium containing these viruses for 2 h, after which an equivalent volume of culture medium containing 10% FBS was added for an additional overnight incubation at 37°C in a cell culture incubator. The infection medium was then replaced with a virus-free medium, and the cultures were returned to the incubator for 48 h prior to each experiment. On the day of the experiment, transduced β-cells were positively identified using an EYFP filter set, and measurements of [Ca2+]i were then performed using a fura-2 filter set (Kang et al. 2005).
Protein kinase A activation assay
Protein kinase A activity in lysates of mouse islets was measured using a PepTag Non-Radioactive cAMP-Dependent Protein Kinase Assay kit (Promega, Madison, WI, USA). Prior to their lysis, islets were exposed to acetoxymethyl esters of PKA- or Epac-selective cAMP analogues for 30 min while equilibrated at 37°C in culture medium containing 5.6 mm glucose and gassed with 95% air and 5% CO2. Islets were homogenized in a PKA extraction buffer, after which the crude homogenate was subjected to centrifugation (14,000g) for 5 min at 4°C. The supernatant fraction was collected and assayed for PKA activity by addition of a PepTag A1 Peptide that is a fluorescent Kemptide [LRRASLG]. The phosphorylated form of PepTag A1 Peptide was resolved by electrophoresis on a 0.8% agarose gel (100 V, 15 min) and quantified using a ChemiDoc XRS and Quantity One image analysis software (Bio-Rad, Hercules, CA, USA).
Western blot detection of PLC-ɛ
The methods for immunoprecipitation and immunoblot detection of PLC-ɛ were as described previously (Wang et al. 2005) except that lysates of mouse islets or donor human islets were used as the starting material. Phospholipase C-ɛ was immunoprecipitated using a 1:500 dilution of a rabbit polyclonal antiserum (2933) that recognizes the RA2 domain of PLC-ɛ. After resolution of the immunoprecipitated proteins by SDS-PAGE, immunodetection of PLC-ɛ was performed using a 1:6000 dilution of a rabbit polyclonal antiserum (2163) that recognizes the RA1 domain of PLC-ɛ. The secondary antiserum was a 1:10 000 dilution of a goat anti-rabbit IRDye 800CW (LI-COR Bioscience, Lincoln, NE, USA). Immunoreactivity was detected using a LI-COR Odyssey Infrared Imager.
Immunodetection of Epac2 in mouse β-cells and rat INS-1 cells
Immunofluorescence microscopy was performed using an anti-Epac2 rabbit polyclonal antiserum (Ab1536; 1:100 dilution) as the primary antiserum. The characteristics of this antiserum are described in the Supplemental Material. Mouse β-cells and rat INS-1 cells (Wollheim, Geneva, Switzerland) were fixed in PBS containing 4% paraformaldehyde, and the cells were then permeabilized using 0.2% Triton X-100 dissolved in PBS. The blocking solution contained 5% goat serum and 1% bovine serum albumin in PBS. A 1:1000 dilution of goat anti-rabbit IgG antiserum conjugated to Alexa Fluor 488 (Molecular Probes/Invitrogen, catalogue no. A-11034) served as the secondary antiserum. For detection of insulin immunoreactivity, the primary antiserum was a 1:1000 dilution of a guinea-pig anti-insulin antiserum (Sigma-Aldrich, catalogue no. I-8510), and a 1:1000 dilution of goat anti-guinea-pig IgG antiserum conjugated to Alexa Fluor 594 (Molecular Probes/Invitrogen, catalogue no. A-11076) served as the secondary antiserum. For INS-1 cells, immunofluorescence corresponding to Epac2 was visualized by standard fluorescence light microscopy, and the images were captured for digitization using a ×20 objective and an EMCCD camera (Cascade 512b; Photometrics, Tucson, AZ, USA) mounted on a Nikon TE300 inverted microscope. For mouse β-cells, Epac2 and insulin immunoreactivity was imaged using a LSM510 laser-scanning confocal microscope, a ×100 objective and AxioVision Software (Carl Zeiss, Inc.).
Quantitative PCR for detection of Epac2, PLC-ɛ and GLP-1 receptor mRNA
Reverse transcriptase–quantitative polymerase chain reactions (RT-QPCRs) were performed using QuantiTect Sybr-green one-step kits (Qiagen, Valencia, CA, USA) with approximately 110 ng of template RNA. Reactions were performed using an MJ MiniOpticon cycler with 35 cycles of 94°C for 15 s, 60°C for 30 s and 72°C for 30 s, followed by a melting curve analysis from 60°C to 94°C. Products were then run on 2% agarose gels, products were gel extracted using QIAquick kits (Qiagen), and product identity was confirmed by sequencing. Threshold crossing (Ct) values were set manually, and the differences between the Ct values were calculated for each reaction. The ΔCt values were entered into Origin 8 software (OriginLab, Northampton, MA, USA) for analysis using ANOVA. The PCR primers used to amplify PLC-ɛ were forward, 5′-CCTGCCCATGGACTACCTCTG-3′ and reverse, 5′-GGCCACATGCACCAAATAAGA-3′. For the GLP-1R, the PCR primers were forward, 5′-CACACTGCTGGCCTTCTCGG-3′ and reverse, 5′-GCAGCCCTCGTCCTCATAGAG-3′, and for Epac2 the PCR primers were forward, 5′-CGCCATGCAACCATCGTTACC-3′ and reverse, 5′-GAGCCCGTTTCCATAACACC-3′. An S18 primer set was used to generate a reference PCR product, and the relative abundance of the PCR products was calculated using the ΔΔCt method (Litvak & Schmittgen, 2001).
Sources of reagents and administration of test substances
Phosphate-AM3 (Phosphate tris (acetoxymethyl) ester), N6-benzoyladenosine-3′,5′-cyclic monophosphate acetoxymethyl ester (6-Bnz-cAMP-AM) and 8-pCPT-2′-O-Me-cAMP-AM were from Biolog Life Science Institute (Bremen, Germany). Exendin-4, H-89, thapsigargin and bafilomycin were from Sigma-Aldrich. Ro-31-8220, BIM-1, KN-92 and KN-93 were from Calbiochem. Each test substance was dissolved in SES and, except for H-89, which was bath applied, all test substances were applied to individual cells using glass ‘puffer’ micropipettes (World Precision Instruments, catalogue no. 1B150-6) under the control of a Narishige Instruments MM-203 hydraulic micromanipulator and pressurized with a pneumatic pressure ejection system, as described previously (Holz et al. 1993).
Calcium-induced Ca2+ release is facilitated by exendin-4 and is disrupted in β-cells of PLC-ɛ KO mice
Wild-type (WT) 16- to 28-week-old male mice were used in combination with established methods of UV flash photolysis in order to uncage Ca2+ in NP-EGTA- and fura-2-loaded β-cells equilibrated in SES containing 5.6 mm glucose (Kang et al. 2005). In this single-cell assay, a short-duration (600 μs) flash of low-intensity UV light was delivered to a β-cell through the microscope objective while also monitoring the [Ca2+]i. By uncaging Ca2+ in this manner, it was possible to generate a small (<50 nm) increase of [Ca2+]i that did not generate CICR on its own, either in control conditions (first UV flash of Fig. 1A) or when the uncaging of Ca2+ was paired with the application of a small bolus of SES to the cell (second UV flash of Fig. 1A). However, if the uncaging of Ca2+ was performed while also administering exendin-4 (10 nm), a large transient increase of [Ca2+]i was generated (Fig. 1B). As reported for mouse β-cells previously, this action of exendin-4 was explained by its ability to sensitize the intracellular Ca2+ release mechanism to stimulatory effects of cytosolic Ca2+, thereby allowing CICR to be triggered by the uncaging of Ca2+ (Kang et al. 2005). Note that in these conditions of NP-EGTA loading, exendin-4 failed to stimulate an increase of [Ca2+]i prior to the uncaging of Ca2+ (Fig. 1B). This finding is consistent with our previous study of mouse β-cells, in which we demonstrated that in conditions of NP-EGTA loading, exendin-4 does not depolarize β-cells (Kang et al. 2005). Thus, the UV flash photolysis assay described here allows a selective analysis of the CICR mechanism independent of any confounding depolarizing action of exendin-4 that would stimulate Ca2+ influx through voltage-dependent Ca2+ channels (VDCCs).
We defined the appearance of CICR as a transient increase of [Ca2+]i, the duration of which did not exceed 30 s when measured at the 10% amplitude cut-off (Fig. 1C). An additional requirement was that the increase of [Ca2+]i must have exceeded 200 nm when measured at the 50% amplitude cut-off (Fig. 1C). Using these criteria, population studies were conducted at the single-cell level using β-cells of WT mice. It was found that CICR could be generated in 9% of the β-cells not exposed to exendin-4, whereas 82% of the cells exhibited CICR when they were pretreated with exendin-4 (10 nm; Fig. 1D). When the PKA inhibitor H-89 (10 μm) was included in the SES bathing these exendin-4-treated cells, the percentage of responsive cells decreased from 82 to 55% (Fig. 1D), thereby demonstrating that exendin-4 acted through PKA-dependent and PKA-independent pathways to facilitate CICR.
This analysis was then repeated using 16- to 28-week-old male PLC-ɛ KO mice that were congenic with the WT mice described above. In comparison to findings obtained with WT mouse β-cells, the percentage of exendin-4-treated β-cells exhibiting CICR was reduced for PLC-ɛ KO mouse β-cells not treated with H-89. Thus, 82% of the exendin-4-treated β-cells from WT mice exhibited CICR, whereas only 44% of the β-cells of PLC-ɛ KO mice exhibited CICR (Fig. 1D). Furthermore, in conditions of H-89 treatment, the action of exendin-4 in PLC-ɛ KO mouse β-cells was nearly abrogated (Fig. 1D). In summary, in WT mouse β-cells, exendin-4 was found to facilitate CICR in a manner that was both PKA and PLC-ɛ dependent.
Calcium-induced Ca2+ release is facilitated by the acetoxymethyl esters of PKA- and Epac-selective cAMP analogues
Additional studies were performed using cAMP analogues that activate PKA (6-Bnz-cAMP-AM) or Epac (8-pCPT-2′-O-Me-cAMP-AM) in a selective manner. Such compounds are membrane-permeant acetoxymethyl esters that must be hydrolysed by cytosolic esterases in order to become bioactive (Vliem et al. 2008; Chepurny et al. 2009). To assess the efficacy of these compounds, it was first established that CICR in WT mouse β-cells was not facilitated by phosphate-AM3 (0.3 μm; Fig. 2A). This unsubstituted acetoxymethyl ester serves as a negative control because it does not activate cAMP binding proteins, but it does generate 3 mole equivalents of acetic acid and formaldehyde per mole of phosphate when it is hydrolysed by cytosolic esterases. Having established this negative control, it was then demonstrated that CICR was instead facilitated by PKA-selective 6-Bnz-cAMP-AM (Fig. 2B) and also Epac-selective 8-pCPT-2′-O-Me-cAMP-AM (Fig. 2C; abbreviated as ESCA-AM) when each analogue was tested at a concentration of 1 μm. For 8-pCPT-2′-O-Me-cAMP-AM, this facilitation was not explained by its unexpected ability to activate PKA, as verified in an in vitro PKA activation assay using isolated mouse islets treated with this analogue (Supplemental Material, Fig. S1A). Thus, it was not surprising that the action of 6-Bnz-cAMP-AM to facilitate CICR was blocked by H-89 (10 μm), whereas the action of 8-pCPT-2′-O-Me-cAMP-AM was not (compare insets of Fig. 2B and C; also refer to the statistics concerning this experiment that are presented in Fig. 3E and F).
Calcium-induced Ca2+ release is facilitated by a hydrolysis-resistant Sp-8-pCPT-2′-O-Me-cAMPS
It has recently become appreciated that the non-acetoxymethyl ester 8-pCPT-2′-O-Me-cAMP is metabolized intracellularly via hydrolysis to generate bioactive derivatives of adenosine, and that such derivatives can affect cellular functions in an Epac-independent manner (Laxman et al. 2006). This phenomenon is especially apparent after prolonged exposure (48–96 h) of cells to 8-pCPT-2′-O-Me-cAMP (Enyeart et al. 2010). Importantly, such a confounding metabolic process does not explain the rapid action of 8-pCPT-2′-O-Me-cAMP-AM to facilitate CICR, as reported here. In fact, we found that CICR was facilitated by the Epac activator Sp-8-pCPT-2′-O-Me-cAMPS, a hydrolysis-resistant cAMP analogue that is not metabolized to bioactive derivatives of adenosine (Supplemental Material, Fig. S1B). Given that Sp-8-pCPT-2′-O-Me-cAMPS is not an acetoxymethyl ester, it exerted an expected reduced efficacy in this assay (Supplemental Material, Fig. S1B). Increasing the concentration of Sp-8-pCPT-2′-O-Me-cAMPS from 1 to 100 μm led to a significant increase in the fraction of cells exhibiting CICR (P < 0.05).
Calcium-induced Ca2+ release is generated by the release of Ca2+ from thapsigargin-sensitive Ca2+ stores
The transient increase of [Ca2+]i that was generated in response to the uncaging of Ca2+ in WT mouse β-cells treated with 8-pCPT-2′-O-Me-cAMP-AM signified the mobilization of intracellular Ca2+ due to the fact that it could still be measured in conditions in which β-cells were bathed in SES that was nominally Ca2+ free, or that was supplemented with agents that blocked Ca2+ influx, such as Cd2+, La3+ or diazoxide (Fig. 2D and E). In contrast, the transient increase of [Ca2+]i was not generated in conditions in which the endoplasmic reticulum (ER) Ca2+ content was depleted by treatment with sarcoplasmic–endoplasmic Ca2+-ATPase inhibitor thapsigargin (1 μm; Fig. 2F; Supplemental Material, Fig. S2A). Such findings are expected if 8-pCPT-2′-O-Me-cAMP-AM mobilizes Ca2+ from ER Ca2+ stores (Kang et al. 2005). These ER Ca2+ stores may also be mobilized in a PKA-dependent manner, since thapsigargin treatment also abrogated the action of 6-Bnz-cAMP-AM to release intracellular Ca2+ (Fig. 2F; Supplemental Material, Fig. S2B).
Since recent reports indicate that Epac activators might signal through β-cell nicotinic acid adenine dinucleotide phosphate (NAADP) receptors (i.e. two-pore Ca2+ channels) to mobilize Ca2+ from ‘acidic Ca2+ stores’ located in a non-ER compartment (Kim et al. 2008; Naylor et al. 2009), we also tested the vacuolar H+ ATPase inhibitor bafilomycin A1. This compound disrupts the mobilization of Ca2+ from acidic Ca2+ stores that are under the control of NAADP (Calcraft et al. 2009). When WT mouse β-cells were treated with bafilomycin A1 (1 μm), a gradual increase of the basal [Ca2+]i was measured, and from this new plateau it was still possible to evoke CICR in conditions of UV flash photolysis provided that the cells were also treated with 8-pCPT-2′-O-Me-cAMP-AM (Supplemental Material, Fig. S2C–F). Thus, the facilitatory action of 8-pCPT-2′-O-Me-cAMP-AM measured in this assay of CICR might not be related to the release of Ca2+ from acidic Ca2+ stores, although this possibility remains to be explored in greater detail.
Assessment of CICR in β-cells of Epac2 KO mice
Since no suitable pharmacological antagonist of Epac2 activation exists (Holz et al. 2008), we used global Epac2 KO mice in order to definitively establish a role for Epac2 in the facilitation of CICR by Epac activators. These Epac2 KO mice were generated using a gene trap approach that inserted into intron 1 of RAPGEF4 a transgene incorporating multiple translation stop codons in multiple reading frames (Fig. 3A). The KO of Epac2 in these mice was confirmed by methods of genotyping and RT-PCR (Fig. 3B) and by Western blot analysis using a monoclonal (5B1) anti-Epac2 antibody (Fig. 3C). Importantly, expression of Epac2 was confirmed in the β-cells of WT mice, as detected by immunofluorescence microscopy using a rabbit affinity-purified anti-Epac2 antiserum (Ab1536). This antiserum also recognizes endogenous and recombinant forms of Epac2 in rat INS-1 cells (Fig. 4A and B). Furthermore, Epac2 was also detected in donor human islets, a finding not previously documented using anti-Epac2 antisera (Supplemental Material, Fig. S3).
Using β-cells of Epac2 KO mice, it was demonstrated that the action of exendin-4 (10 nm) to facilitate CICR was reduced but not abrogated relative to the action of exendin-4 in WT mouse β-cells (Fig. 3D). This analysis also demonstrated that in β-cells of WT mice, the action of exendin-4 was only partly inhibited by H-89 (10 μm), and that the H-89-resistant action of exendin-4 was reduced in β-cells of Epac2 KO mice (Fig. 3D). Importantly, this analysis also revealed that the action of 8-pCPT-2′-O-Me-cAMP-AM to facilitate CICR was strongly suppressed in β-cells of Epac2 KO mice, as measured in conditions in which β-cells were not treated, or treated, with H-89 (Fig. 3E). In contrast, 6-Bnz-cAMP-AM retained its ability to facilitate CICR in β-cells of Epac2 KO mice not treated with H-89, whereas little or no action of 6-Bnz-cAMP-AM was measurable after treatment of these β-cells with H-89 (Fig. 3F). In summary, in conditions in which Epac2 expression was ablated, the Ca2+ mobilizing action of exendin-4 was diminished, the action of 8-pCPT-2′-O-Me-cAMP-AM was abrogated, and the action of 6-Bnz-cAMP-AM was unaffected.
8-pCPT-2′-O-Me-cAMP-AM fails to facilitate CICR in β-cells of PLC-ɛ KO mice
Phospholipase C-ɛ was detectable by Western blot analysis (Fig. 5A and B) and by PCR analysis (Fig. 5C and D) using mouse islets and also donor human islets. Thus, attention turned to evaluating the functional consequences of the PLC-ɛ KO when testing PKA- and Epac-selective cAMP analogues. Using an approach identical to that described for Epac2 KO mice, it was demonstrated that 6-Bnz-cAMP-AM retained its efficacy to facilitate CICR in β-cells of PLC-ɛ KO mice (Fig. 6A), whereas 8-pCPT-2′-O-Me-cAMP-AM was ineffective (Fig. 6B). This reduced efficacy of 8-pCPT-2′-O-Me-cAMP-AM in β-cells of PLC-ɛ KO mice was unlikely to be explained by a reduction of ER Ca2+ content. This fact was established by demonstrating that the amplitudes of the cytosolic Ca2+ transients measured in conditions of UV flash photolysis were nearly identical when evaluating the action of 6-Bnz-cAMP-AM (1 μm) to facilitate CICR in β-cells of WT mice vs. PLC-ɛ KO mice (1,205 ± 120 nm for n= 11 WT β-cells vs. 1,156 ± 140 nm for n= 12 PLC-ɛ KO β-cells). As predicted, in β-cells of PLC-ɛ KO mice the action of 6-Bnz-cAMP-AM was fully blocked by H-89 (Fig. 6A), whereas the small and non-significant residual action of 8-pCPT-2′-O-Me-cAMP-AM was not significantly reduced by H-89 (Fig. 6B). Taken together, these findings provide strong support for a model in which there exist not only PKA- but also Epac2-mediated actions of cAMP to facilitate CICR. More importantly, these findings obtained using PLC-ɛ KO mice indicate that PLC-ɛ serves as the principal effector signalling molecule in support of CICR that is facilitated by activators of Epac2 but not PKA.
Evidence that CICR is regulated by PKC and Ca2+/calmodulin-regulated protein kinase II
Epac-selective cAMP analogues stimulate the release of Ca2+ from the sarcoplasmic reticulum of adult mouse and rat ventricular cardiomyocytes (Oestreich et al. 2007, 2009; Pereira et al. 2007). Such actions of the analogues are mediated by protein kinase C-ɛ (PKC-ɛ) and Ca2+/calmodulin-regulated protein kinase II (CaMKII) acting in their roles as downstream effectors of PLC-ɛ. In fact, the PKC-ɛ-mediated phosphorylation of CaMKII is proposed to play a key role in regulating the function of ryanodine receptor (RYR2) Ca2+ release channels in adult mouse ventricular cardiomyocytes (Oestreich et al. 2009). Therefore, it is remarkable that in WT mouse β-cells, bath application of the PKC inhibitors Ro-31–8220 and BIM-1 suppressed the action of 8-pCPT-2′-O-Me-cAMP-AM to facilitate CICR (Fig. 6C). Furthermore, CICR was also suppressed by the CaMKII inhibitor KN-93, whereas KN-92 was inactive (Fig. 6D; KN-92 does not inhibit CaMKII). These effects of PKC and CaMKII inhibitors were measurable when each was tested at concentrations (1–10 μm) that disrupt Epac1- and PLC-ɛ-regulated CICR in cardiomyocytes (Pereira et al. 2007; Oestreich et al. 2009).
Recombinant PLC-ɛ rescues CICR in β-cells of PLC-ɛ KO mice
The failure of 8-pCPT-2′-O-Me-cAMP-AM to facilitate CICR in β-cells of PLC-ɛ KO mice might simply result from the absence of PLC-ɛ in these cells. Alternatively, there might exist compensatory processes (e.g. reduced Epac2 or Rap GTPase expression; upregulation of RapGAP activity) that are initiated by the KO of PLC-ɛ, and that disrupt CICR by virtue of their abilities to alter signalling pathways that are Epac2 and Rap dependent, but that do not involve PLC-ɛ. The first of these two alternative possibilities is the more likely explanation because the facilitation of CICR by 8-pCPT-2′-O-Me-cAMP-AM could be rescued after transduction of PLC-ɛ KO β-cells with a bicistronic adenovirus that directed expression of WT recombinant PLC-ɛ in combination with EYFP. In this assay, EYFP served as a fluorescent marker with which to obtain a positive identification of transduced cells in conditions of imaging that still allowed accurate fura-2-based measurements of [Ca2+]i (Kang et al. 2005).
Using these imaging techniques, it was first demonstrated that 8-pCPT-2′-O-Me-cAMP-AM (1 μm) failed to alter [Ca2+]i in PLC-ɛ KO mouse β-cells that were transduced with EYFP but not PLC-ɛ, and that were NP-EGTA loaded but not subjected to UV flash photolysis (Fig. 7A). The experiment was then repeated using PLC-ɛ KO mouse β-cells transduced with EYFP and also recombinant PLC-ɛ. Remarkably, the cells expressing EYFP and recombinant PLC-ɛ were extremely sensitive to 8-pCPT-2′-O-Me-cAMP-AM (1 μm) such that oscillations of [Ca2+]i were induced in the absence of UV flash photolysis (Fig. 7B). Although the nature of these oscillations was not investigated, such findings are understandable if high-level expression of recombinant PLC-ɛ in PLC-ɛ KO β-cells allows a more efficient coupling of endogenous Epac2 activation to the mobilization of intracellular Ca2+. This conclusion is supported by the finding that no such oscillations of [Ca2+]i were measured when the concentration of 8-pCPT-2′-O-Me-cAMP-AM was reduced to 0.3 μm (Fig. 7C).
Having established that a lower concentration of 8-pCPT-2′-O-Me-cAMP-AM (0.3 μm) failed to alter basal [Ca2+]i in PLC-ɛ KO mouse β-cells transduced with recombinant PLC-ɛ, it was then possible to perform a UV flash photolysis assay in which this same concentration of 8-pCPT-2′-O-Me-cAMP-AM was evaluated for its potential ability to facilitate CICR. It was demonstrated that transduction of PLC-ɛ KO mouse β-cells with recombinant PLC-ɛ rescued the action of 8-pCPT-2′-O-Me-cAMP-AM (0.3 μm) to facilitate CICR initiated by the uncaging of Ca2+ (Fig. 7D and F). However, no such rescue occurred when PLC-ɛ KO β-cells were transduced with EYFP alone (Fig. 7E and F). It may be concluded that the absence of PLC-ɛ expression does in fact explain the loss-of-function phenotype in which activators of Epac2 failed to facilitate CICR in the β-cells of PLC-ɛ KO mice.
Facilitation of CICR by 8-pCPT-2′-O-Me-cAMP-AM is contingent on PLC-ɛ catalytic and Rap binding activities
Using the rescue protocol described for Fig. 7D, we sought to determine to what extent the catalytic and Rap binding activities of PLC-ɛ were important to the overall process by which CICR was facilitated by 8-pCPT-2′-O-Me-cAMP-AM. To this end, β-cells of PLC-ɛ KO mice were transduced with WT PLC-ɛ or mutant forms of PLC-ɛ that contained amino acid substitutions that rendered the enzyme catalytically dead (H1640L) or incapable of Rap binding (K2150E; Fig. 8A). This analysis revealed that WT PLC-ɛ rescued the action of 8-pCPT-2′-O-Me-cAMP-AM (0.3 μm) to facilitate CICR, whereas no such rescue was measurable after transduction with either H1640L or K2150E PLC-ɛ. This outcome was the case even after raising the concentration of 8-pCPT-2′-O-Me-cAMP-AM to 1 μm (Fig. 8B). Thus, the catalytic and Rap binding activities of PLC-ɛ are indispensable in order for PLC-ɛ to serve as an Epac2 effector with Ca2+ mobilizing functions.
Downregulation of Rap GTPase activity disrupts Epac2- but not PKA-regulated CICR
Since cAMP signals through Epac and Rap to activate PLC-ɛ in other cell types, it may be predicted that in β-cells of WT mice, the downregulation of Rap activity will uncouple Epac2 activation from the facilitation of CICR. This possibility was tested by transducing β-cells with a bicistronic adenovirus directing expression of EYFP and a RapGAP that is a GTPase activating protein and that stimulates the conversion of Rap from an active GTP-bound form to an inactive GDP-bound form (Bos et al. 2007). We found that in conditions of UV flash photolysis in which Ca2+ was uncaged from NP-EGTA, the action of 8-pCPT-2′-O-Me-cAMP-AM (1 μm) to facilitate CICR was abrogated in WT β-cells expressing RapGAP (Fig. 8C and D). This functional antagonism was highly selective, in that RapGAP failed to influence the ability of PKA activator 6-Bnz-cAMP-AM (1 μm) to facilitate CICR (Fig. 8C and E).
Phospholipase C-ɛ is a novel Epac2- and Rap1-regulated phospholipase expressed in islet β-cells
Although GLP-1R signal transduction in β-cells involves the cAMP-dependent activation of both PKA and Epac2, there exists controversy concerning whether or not GLP-1 can act independently of PKA and instead via Epac2 to stimulate Ca2+ signalling and insulin secretion (Renstrom et al. 1997; Bode et al. 1999; Kang et al. 2001; Eliasson et al. 2003; Gromada et al. 2004; Holz, 2004; Seino & Shibasaki, 2005; Thams et al. 2005; Hatakeyama et al. 2006, 2007; Kwan et al. 2007; Shibasaki et al. 2007; Chepurny et al. 2010; Idevall-Hagren et al. 2010). In fact, only one published study clearly links GLP-1R activation to the Epac2-dependent stimulation of islet insulin secretion, as studied in mouse islets treated with Epac2 antisense deoxyoligonucleotides (Kashima et al. 2001). Furthermore, although Epac2 is reported to act through its immediate effector Rap1 GTPase to potentiate glucose-stimulated insulin secretion from mouse islets (Shibasaki et al. 2007), exactly how activated Rap1 promotes the Ca2+-dependent exocytosis of insulin from β-cells has remained uncertain. Thus, the new findings presented here are significant in that we document the expression and functionality of a novel Epac2- and Rap1-regulated PLC-ɛ, the activation of which couples β-cell GLP-1R occupancy to the facilitation of CICR that mobilizes intracellular Ca2+. Given that an analogous mechanism of Epac2-regulated CICR is known to be coupled to Ca2+-dependent exocytosis in human β-cells (Kang et al. 2003), and since the selective Epac activator 8-pCPT-2′-O-Me-cAMP-AM exerts a powerful insulin secretagogue action in both human and mouse islets (Chepurny et al. 2009, 2010; Kelley et al. 2009), it would appear that Epac2 and PLC-ɛ participate in β-cell stimulus–secretion coupling that is under the control of the GLP-1R.
Unexpected molecular properties of CICR in mouse β-cells
It is particularly surprising that we find that the Epac2-mediated Ca2+ mobilizing action of GLP-1R agonist exendin-4 requires expression of a phosphoinositide (PI) specific PLC-ɛ in mouse β-cells. This is unexpected because in earlier studies it was reported that GLP-1R agonists failed to stimulate 3H-inositol phosphate (3H-IP) release from myo-[2-3H]-inositol prelabelled rat islets and rat INS-1 insulin-secreting cells (Fridolf & Ahren, 1991; Widmann et al. 1994; Kang et al. 2003). Such negative findings concerning PI hydrolysis were interpreted to indicate that the Ca2+ mobilizing action of GLP-1 in β-cells was unrelated to PLC activation. Instead, it was proposed that GLP-1 mobilizes Ca2+ by sensitizing intracellular Ca2+ release channels to stimulatory effects of IP3 and Ca2+ (Gromada et al. 1995; Holz et al. 1999; Dyachok & Gylfe, 2004). Specifically, it was proposed that GLP-1 mobilizes Ca2+ in β-cells by promoting PKA-mediated phosphorylation of intracellular Ca2+ release channels, and that these channels correspond to IP3 receptors and ryanodine receptors (Gromada et al. 1995; Holz et al. 1999; Dyachok & Gylfe, 2004).
With these points in mind, it is significant that the new findings presented here do in fact confirm a PKA-mediated action of exendin-4 to mobilize Ca2+, an action measurable in β-cells of Epac2 and PLC-ɛ KO mice. However, our studies of these same KO mice reveal a previously unrecognized Ca2+ mobilizing action of exendin-4, one that requires β-cell expression of Epac2 and PLC-ɛ. Since this PKA-independent action of exendin-4 is mimicked by 8-pCPT-2′-O-Me-cAMP-AM, and since the action of 8-pCPT-2′-O-Me-cAMP-AM is blocked by inhibitors of PKC and CaMKII, it could be that the GLP-1R does in fact signal through Epac2 and PLC-ɛ to stimulate PI hydrolysis and to modulate intracellular Ca2+ release channel function. This concept is consistent with previous reports that GLP-1 activated PKC in INS-1 cells (Suzuki et al. 2006), whereas 8-pCPT-2′-O-Me-cAMP-AM promoted PI hydrolysis in INS-1 cells (Leech et al. 2010). Furthermore, GLP-1 was reported to stimulate 3H-IP release from COS cells expressing the recombinant GLP-1R (Wheeler et al. 1993), from frog oocytes expressing the recombinant GLP-1R (Gromada et al. 1998) and from mouse βTC3 insulin-secreting cells expressing the endogenous GLP-1R (Gromada et al. 1995). In summary, a key issue that remains to be resolved concerns whether or not the Epac2-mediated action of exendin-4 to facilitate β-cell CICR results from PI hydrolysis and, if so, whether it is IP3 generation or PKC activation that controls the function of IP3 or ryanodine receptors.
Potential physiological significance of CICR in mouse β-cells
Since depolarization-induced Ca2+ influx is already well established to be a direct stimulus for insulin secretion (Eliasson et al. 2008), it is reasonable to question whether CICR is of major physiological significance to β-cell stimulus–secretion coupling. In fact, in one prior study of mouse β-cells, no coupling of CICR to exocytosis was measurable, and the emptying of ER Ca2+ stores by treatment with thapsigargin failed to reduce islet insulin secretion stimulated by glucose (Zhang et al. 2007). Unfortunately, the interpretation of this prior study is not clear-cut due to the fact that exocytosis was studied in conditions in which β-cells were not treated with cAMP-elevating agents. This is an important consideration because in the present study we found that in the absence of cAMP-elevating agents, CICR was rarely triggered in mouse β-cells. With these points in mind, we argue that an amplification mechanism exists for β-cell exocytosis, one that requires CICR and that is only operational when β-cells are treated with cAMP-elevating agents. This concept is based on prior studies in which cAMP was found to act through PKA to increase the size of a highly Ca2+-sensitive pool of insulin secretory granules (Wan et al. 2004; Yang & Gillis, 2004). Specifically, we propose that in the absence of cAMP-elevating agents, exocytosis stimulated by glucose will be restricted to a small number of secretory granules that are co-localized with VDCCs at the plasma membrane. These secretory granules are predicted to undergo exocytosis in response to the large (10–20 μm) increase of [Ca2+]i that occurs at the inner mouths of VDCCs when these channels open in response to glucose metabolism-dependent membrane depolarization. In the presence of both GLP-1 and glucose, cAMP will act through PKA to increase the number of highly Ca2+-sensitive secretory granules that are located near the plasma membrane, but that are not docked and co-localized with VDCCs. Thus, in conditions in which Epac2 is activated and CICR is facilitated, a more modest (500 nm to 2.0 μm) and globally distributed increase of [Ca2+]i will trigger the exocytosis of a much larger number of secretory granules present within the highly Ca2+-sensitive pool. This model is compatible with our previous study demonstrating an ability of CICR to initiate ‘summating’ exocytosis, as detected using the methods of carbon fibre amperometry (Kang & Holz, 2003).
Although the new findings presented here document a mechanism of GLP-1R-regulated CICR in β-cells, it is noteworthy that GLP-1 receptors are also expressed in the heart, and in fact GLP-1R agonists are under investigation for their potential usefulness in the treatment of cardiovascular diseases (Fields et al. 2009; Treiman et al. 2010). Furthermore, the heart also contains a receptor for the metabolite of GLP-1 designated as GLP-1 (9–36)-amide and, as is the case for GLP-1, this metabolite is capable of stimulating cAMP production in cardiomyocytes (Ban et al. 2008, 2010). Given that the β-cell GLP-1R signals through Epac2 to facilitate CICR, and in view of the fact that Epac-selective cAMP analogues act via Epac1 and possibly Epac2 to regulate multiple parameters of cardiomyocyte function (Morel et al. 2005; Somekawa et al. 2005; Oestreich et al. 2007, 2009; Pereira et al. 2007; Hothi et al. 2008; Métrich et al. 2008, 2010; Cazorla et al. 2009; Duquesnes et al. 2010; Mangmool et al. 2010), it could be that GLP-1R agonists currently in use for the treatment of type 2 diabetes mellitus might have the additional ability to act in an Epac-mediated manner to exert therapeutically important actions in the myocardium.
All authors contributed to the conception and design of the study, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content and final approval of the version to be published.
We wish to thank Dr. Frank Schwede of the BIOLOG Life Sci. Inst. for the gift of cAMP analogs. Funding was provided by the National Institutes of Health (DK045817, DK069575 to G.G.H.; DK074966 to M.W.R.; NS5051383, AG033282 to Y.L.; and R01GM053536 to A.V.S.) and the American Diabetes Association (Research Award to C.A.L.).